BMC Cancer 2008, 8:57 http://www.biomedcentral.com/1471-2407/8/57 20. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD, Lechler RI: Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001, 98(9):2736-2744. 21. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3.[see com- ment]. Science 2003, 299(5609):1057-1061. 22. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, Maeda M, Onodera M, Uchiyama T, Fujii S, Sakaguchi S: Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. International Immunology 2004, 16(11):1643-1656. 23. Schreiber TH: The Use of FoxP3 as a Biomarker and Prognos- tic Factor for Malignant Human Tumors. Cancer Epidemiol Biomarkers Prev 2007, 16(10):1931-1934. 24. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evde- mon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knut- son KL, Chen L, Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and pre- dicts reduced survival. Nature Medicine 2004, 10(9):942-949. 25. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pan- creas or breast adenocarcinoma. J Immunol 2002, 169(5):2756-2761. 26. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology 2006, 24(34):5373-5380. 27. Liang S, Alard P, Zhao Y, Parnell S, Clark SL, Kosiewicz MM: Conver- sion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. Journal of Experimental Medicine 2005, 201(1):127-137. 28. Krupnick AS, Gelman AE, Barchet W, Richardson S, Kreisel FH, Turka LA, Colonna M, Patterson GA, Kreisel D: Murine vascular endothelium activates and induces the generation of alloge- neic CD4+25+Foxp3+ regulatory T cells. J Immunol 2005, 175(10):6265-6270. 29. Aramaki O, Shirasugi N, Takayama T, Shimazu M, Kitajima M, Ikeda Y, Azuma M, Okumura K, Yagita H, Niimi M: Programmed death-1- programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen. Transplantation 2004, 77(1):6-12. 30. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167(3):1245-1253. 31. Kitazawa Y, Fujino M, Wang Q, Kimura H, Azuma M, Kubo M, Abe R, Li XK: Involvement of the programmed death-1/pro- grammed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplanta- tion 2007, 83(6):774-782. 32. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-express- ing tumor cells. Int J Cancer 2007. 33. Armstrong A, Dermime S: Developing effective cancer vaccines: design and monitoring are critical. Br J Cancer 2001, 84(11):1433-1436. 34. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH: Tissue expres- sion of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006, 203(4):883-895. 35. Blank C, Gajewski TF, Mackensen A: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mecha- nism of immune evasion: implications for tumor immuno- therapy. Cancer Immunol Immunother 2005, 54(4):307-314. 36. Bala KK, Moudgil KD: Induction and maintenance of self toler- ance: the role of CD4+CD25+ regulatory T cells. Arch Immunol Ther Exp (Warsz) 2006, 54(5):307-321. 37. Beyer M, Schultze JL: Regulatory T cells in cancer. Blood 2006, 108(3):804-811. 38. Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC, Seow HF: Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 2006, 102(2):229-236. 39. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198(12):1875-1886. 40. Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH: De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci U S A 2005, 102(11):4103-4108. 41. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infil- trating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006, 107(9):3639-3646. 42. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P: CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006, 177(10):7398-7405. 43. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM: Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003, 97(3):545-553. 44. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM: Time-dependence of hazard ratios for prog- nostic factors in primary breast cancer. Breast Cancer Res Treat 1998, 52(1–3):227-237. 45. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qim- ron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Gar- ber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K: Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11(3):259-273. 46. Marie JC, Letterio JJ, Gavin M, Rudensky AY: TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005, 201(7):1061-1067. 47. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59(13):3128-3133. 48. Keir ME, Freeman GJ, Sharpe AH: PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tis- sues. J Immunol 2007, 179(8):5064-5070. 49. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM: PD-1:PD-L inhibitory path- way affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002, 32(3):634-643. 50. Ahmadzadeh M, Rosenberg SA: IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006, 107(6):2409-2414. 51. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, Pratap S, Toms C, Fox BC, Cerundolo V, Powrie F, Banham AH: Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005, 35(6):1681-1691. 52. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439(7077):682-687. 53. Zabala M, Lasarte JJ, Perret C, Sola J, Berraondo P, Alfaro M, Larrea E, Prieto J, Kramer MG: Induction of immunosuppressive mole- cules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol 2007, 1:1. 54. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhir- sch A: Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 2007, 7(9):1225-1241. 55. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer ther- apeutic immunity. Cancer Res 2005, 65(3):1089-1096. 56. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J: Enhancement of vaccine- mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115(12):3623-3633. Page 11 of 12 (page number not for citation purposes)